CooperCompanies shares plunged to a 52-week low of $51.08 on Thursday, down nearly 20% from Wednesday's close, after the vision care company lowered its full-year revenue and EPS guidance. Both fiscal 2026 guidance ranges now sit below consensus figures. The company also decided after a strategic review not to sell its women's health-centered CooperSurgical division, a move BNP Paribas analyst Navann Ty said may have contributed to the share decline. Ty added that CooperSurgical's flat organic growth in FY26 Q3 was another setback relative to competitors' operating performance. Cooper shares were down about 14% in Thursday afternoon trading.
The Cooper Companies, IncCooperCompanies cut its full-year revenue and EPS guidance below consensus, driving shares to a 52-week low.
BNP Paribas SA